Advertisement

Topics

Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol® for the Treatment of the Signs and Symptoms of Dry Eye Disease

08:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ESSENCE Phase 2b/3 Trial Commences with First Patient Randomized in U.S. Top Line Data Expected Third Quarter 2018 CyclASol® May Overcome the Intolerability Profiles of Current ...

Other Sources for this Article

Novaliq GmbH
For US:
Michael O’Rourke, + 1 813 323 1438
Strategic Consultant, ext.
mrourke@novaliq.com
or
For EU/Asia:
Heidrun Kirsch + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com

NEXT ARTICLE

More From BioPortfolio on "Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol® for the Treatment of the Signs and Symptoms of Dry Eye Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...